Ensoma launches in Boston with $70M Series A to commercialize Engenious gene‑editing adenoviral vectors developed by Fred Hutch and UW researchers

Boston-based biotech spinout Ensoma launched, announcing a $70 million Series A to commercialize Engenious adenoviral vectors developed by Drs. Hans-Peter Kiem (Fred Hutch) and André Lieber (UW) that aim to deliver single‑injection gene therapies without stem cell harvest or chemotherapy.

UUniversity of Washington FFred Hutchinson Cancer Center